Table 3.
Treatment-Related Adverse Events
Event, n (%) | Third-or Later-Line Nivolumab (n = 109) |
|
---|---|---|
Any Grade | Grade 3–4 | |
Any event | 60 (55.0) | 13 (11.9) |
Any serious event | 9 (8.3) | 8 (7.3) |
Any event leading to discontinuation | 3 (2.8) | 3 (2.8) |
Most frequent events (≥5%) | ||
Pruritus | 14 (12.8) | 0 |
Fatigue | 11 (10.1) | 1 (0.9) |
Nausea | 8 (7.3) | 0 |
Rash | 7 (6.4) | 1 (0.9) |
Diarrhea | 7 (6.4) | 0 |
Decreased appetite | 6 (5.5) | 1 (0.9) |
Data are based on a database lock date of November 6, 2017. Safety analysis included all patients who received at least one dose of the study drug. Includes events reported from the time of the first dose of study drug to 30 days after the last dose.